• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

新型冠状病毒肺炎所致肺纤维化的抗纤维化治疗：病例报告

Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation.

作者信息

Sakızcı Uyar Bahar, Ensarioğlu Kerem, Kurt E Bahar, Özkan Derya, Özbal Güneş Serra

机构信息

Department of Anesthesiology and Reanimation, University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey.

Department of Pulmonary Medicine, University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Ankara, Turkey.

出版信息

Turk J Anaesthesiol Reanim. 2022 Jun;50(3):228-231. doi: 10.5152/TJAR.2021.20450.

DOI:10.5152/TJAR.2021.20450
PMID:35801331
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9361135/
Abstract

Coronavirus disease 19 infection clinical presentation varies from asymptomatic cases to acute respiratory distress syndromes. In some cases, pulmonary fibrosis is observed after or during the disease. Pirfenidone is an agent approved for the treatment of idiopathic pulmonary fibrosis. Here we report a patient treated with pirfenidone for pulmonary fibrosis related to coronavirus disease 19.

摘要

新型冠状病毒肺炎感染的临床表现从无症状病例到急性呼吸窘迫综合征不等。在某些情况下，疾病期间或之后会观察到肺纤维化。吡非尼酮是一种被批准用于治疗特发性肺纤维化的药物。在此，我们报告一名使用吡非尼酮治疗与新型冠状病毒肺炎相关的肺纤维化患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0acc/9361135/23cf39eca1a9/tjar-50-3-228_f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0acc/9361135/651a46118d60/tjar-50-3-228_f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0acc/9361135/23cf39eca1a9/tjar-50-3-228_f003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0acc/9361135/651a46118d60/tjar-50-3-228_f002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0acc/9361135/23cf39eca1a9/tjar-50-3-228_f003.jpg

相似文献

1
Anti-fibrotic Treatment for Pulmonary Fibrosis Induced by COVID-19: A Case Presentation.新型冠状病毒肺炎所致肺纤维化的抗纤维化治疗：病例报告
Turk J Anaesthesiol Reanim. 2022 Jun;50(3):228-231. doi: 10.5152/TJAR.2021.20450.
2
Patient and site characteristics associated with pirfenidone and nintedanib use in the United States; an analysis of idiopathic pulmonary fibrosis patients enrolled in the Pulmonary Fibrosis Foundation Patient Registry.与在美国使用吡非尼酮和尼达尼布相关的患者和部位特征；对特发性肺纤维化患者登记在册的 Pulmonary Fibrosis Foundation 患者注册中心的分析。
Respir Res. 2020 Feb 10;21(1):48. doi: 10.1186/s12931-020-1315-4.
3
Real-life experiences in a single center: efficacy of pirfenidone in idiopathic pulmonary fibrosis and fibrotic idiopathic non-specific interstitial pneumonia patients.单中心真实世界经验：吡非尼酮治疗特发性肺纤维化和特发性非特异性间质性肺炎纤维化患者的疗效。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620963015. doi: 10.1177/1753466620963015.
4
Upregulation of RGS2: a new mechanism for pirfenidone amelioration of pulmonary fibrosis.RGS2的上调：吡非尼酮改善肺纤维化的新机制。
Respir Res. 2016 Aug 22;17(1):103. doi: 10.1186/s12931-016-0418-4.
5
Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis.病例报告：吡非尼酮治疗新冠后肺纤维化
Front Med (Lausanne). 2022 Jun 6;9:925703. doi: 10.3389/fmed.2022.925703. eCollection 2022.
6
Pulmonary Fibrosis After COVID-19 Pneumonia.新型冠状病毒肺炎后的肺纤维化
Cureus. 2021 Mar 16;13(3):e13923. doi: 10.7759/cureus.13923.
7
Pirfenidone Improves Familial Idiopathic Pulmonary Fibrosis without Affecting Serum Periostin Levels.吡非尼酮可改善家族性特发性肺纤维化，而不影响血清骨膜蛋白水平。
Medicina (Kaunas). 2019 May 17;55(5):161. doi: 10.3390/medicina55050161.
8
The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?吡非尼酮在抗击由 SARS-CoV-2 引起的炎症和纤维化状态中的附加价值：抗炎和抗纤维化治疗能否解决感染的肺部并发症？
Eur J Clin Pharmacol. 2020 Nov;76(11):1615-1618. doi: 10.1007/s00228-020-02947-4. Epub 2020 Jun 27.
9
Successful Concomitant Therapy with Pirfenidone and Nintedanib in Idiopathic Pulmonary Fibrosis: A Case Report.吡非尼酮与尼达尼布联合治疗特发性肺纤维化成功：一例报告
Respiration. 2016;91(4):327-32. doi: 10.1159/000444690. Epub 2016 Apr 14.
10
Tissue and Bronchoalveolar Lavage Biomarkers in Idiopathic Pulmonary Fibrosis Patients on Pirfenidone.特发性肺纤维化患者服用吡非尼酮的组织和支气管肺泡灌洗液生物标志物。
Lung. 2018 Oct;196(5):543-552. doi: 10.1007/s00408-018-0140-8. Epub 2018 Jul 31.

引用本文的文献

1
Pirfenidone in post-COVID-19 pulmonary fibrosis (FIBRO-COVID): a phase 2 randomised clinical trial.吡非尼酮治疗新冠后肺纤维化（FIBRO-COVID）：一项2期随机临床试验
Eur Respir J. 2025 Apr 24;65(4). doi: 10.1183/13993003.02249-2024. Print 2025 Apr.
2
SARS-CoV-2 Spike Protein Induces Oxidative Stress and Senescence in Mouse and Human Lung.SARS-CoV-2 刺突蛋白诱导小鼠和人肺中的氧化应激和衰老。
In Vivo. 2024 Jul-Aug;38(4):1546-1556. doi: 10.21873/invivo.13605.
3
Strengthening pharmacotherapy research for COVID-19-induced pulmonary fibrosis.

本文引用的文献

1
Successful treatment with methyl-prednisolone pulses for the late phase of COVID-19 with respiratory failure: A single-center case series.甲泼尼龙脉冲治疗 COVID-19 晚期呼吸衰竭的疗效：一项单中心病例系列研究。
Respir Med Case Rep. 2020;31:101318. doi: 10.1016/j.rmcr.2020.101318. Epub 2020 Dec 9.
2
Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19.出院并不意味着治疗结束：注意重型 COVID-19 引发的肺纤维化。
J Med Virol. 2021 Mar;93(3):1378-1386. doi: 10.1002/jmv.26634. Epub 2020 Nov 1.
3
A living WHO guideline on drugs for covid-19.
加强针对新冠病毒感染所致肺纤维化的药物治疗研究。
World J Clin Cases. 2024 Feb 16;12(5):875-879. doi: 10.12998/wjcc.v12.i5.875.
关于新冠病毒药物的世界卫生组织实用指南。
BMJ. 2020 Sep 4;370:m3379. doi: 10.1136/bmj.m3379.
4
Serious adverse events with tocilizumab: Pharmacovigilance as an aid to prioritize monitoring in COVID-19.托珠单抗的严重不良事件：药物警戒作为 COVID-19 监测重点的辅助手段。
Br J Clin Pharmacol. 2021 Mar;87(3):1533-1540. doi: 10.1111/bcp.14459. Epub 2020 Jul 26.
5
The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2 : Anti-inflammatory and anti-fibrotic therapy could solve the lung complications of the infection?吡非尼酮在抗击由 SARS-CoV-2 引起的炎症和纤维化状态中的附加价值：抗炎和抗纤维化治疗能否解决感染的肺部并发症？
Eur J Clin Pharmacol. 2020 Nov;76(11):1615-1618. doi: 10.1007/s00228-020-02947-4. Epub 2020 Jun 27.
6
Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.托珠单抗治疗伴有炎症过度反应和急性呼吸衰竭的重症 COVID-19 肺炎：意大利布雷西亚单中心 100 例患者研究。
Autoimmun Rev. 2020 Jul;19(7):102568. doi: 10.1016/j.autrev.2020.102568. Epub 2020 May 3.
7
Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.中国武汉严重 COVID-19 患者的临床病程和结局：一项单中心、回顾性、观察性研究。
Lancet Respir Med. 2020 May;8(5):475-481. doi: 10.1016/S2213-2600(20)30079-5. Epub 2020 Feb 24.
8
Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.吡非尼酮治疗无法分类的进行性纤维化间质性肺疾病患者：一项双盲、随机、安慰剂对照、2 期临床试验。
Lancet Respir Med. 2020 Feb;8(2):147-157. doi: 10.1016/S2213-2600(19)30341-8. Epub 2019 Sep 29.
9
Idiopathic Pulmonary Fibrosis.特发性肺纤维化
N Engl J Med. 2018 Aug 23;379(8):797-798. doi: 10.1056/NEJMc1807508.
10
Pirfenidone ameliorates lipopolysaccharide-induced pulmonary inflammation and fibrosis by blocking NLRP3 inflammasome activation.吡非尼酮通过阻断 NLRP3 炎性小体激活来改善脂多糖诱导的肺炎症和纤维化。
Mol Immunol. 2018 Jul;99:134-144. doi: 10.1016/j.molimm.2018.05.003. Epub 2018 May 26.